-
-
-
-
-
-
-
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
-
-
-
-
-
-
-
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Promotes Mark Schneyer to CFO, Executive VP
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Acquires CerSci Therapeutics
-
-
-
-
-
-
-
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
-
-
-
-
-
-
-
Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more...)
-
1,157,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

